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Abbreviations: SC, stem cells; MSC, mesenchymal stem cells; 
AT, adipose tissue; GDNF, glial cell derived neuro trophic factor 
[Homo sapiens (human)]; NGFR, nerve growth factor receptor; i/p, 
intraperitoneally
Introduction
Injuries, strokes and cerebral infarctions hold a specific place in the 
range of socially important diseases due to high level of mortality in 
all countries.1–3 Current situation initiates development to completely 
new methods of early diagnostics, therapy and rehabilitation in neuro 
destructive processes management. Small success was achieved 
on the way of increasing effectiveness of therapy at this stage. In 
particular, indications for SC use are broadened along with standard 
therapy of patients with neuro destructive processes. The search for 
“cerebral infarction, stroke, and stem cell” revealed 637 articles in 
PubMed on July 27, 2018. Promising results have been obtained at 
earlier stages of cell technologies combination with standard methods 
of therapy.4–7 However, the number of articles describing side effects 
of cell technologies also increased.8–11
Disadvantages of system injection of stem cells (SC) in 
patients with strokes and brain injuries have been established.10,11 
Scientistsrevealedthatintravenouslyorintraarteriallyadministered 
of SChave extremely low ability to penetrate through blood-brain 
barrier from blood stream to brain tissue. Administration of SC 
into cerebrospinal fluid is complicated by craniocaudal flow of 
liquor. Neurosurgeons inject SC directly into brain tissue, but these 
manipulations are accompanied with additional surgical intervention 
(skull trepanation) worsening patient’s state. Perineural administration 
of mesenchymal stem cells (MSC) into brain appeared to bea 
kind of way out.11–13 Enhancement of this technique allowed using 
somatotopic principle of cranial nerves’ organization for targeted 
migration of SC to specific brain region.11,12,14 In particular, intranasal 
perineural SC injection mainly through the system of olfactory nerves 
can be used in case of stroke located in anterior or middle cranial 
fossa. Localization of destructive focus in posterior cranial fossa 
requires SC injection into the area of trigeminal nerve endings in 
inferior nasal concha or directly into Meckel’s cave. The study was 
aimed at pilot clinical testing of SC perineural transport technique 
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Abstract
Background: Neuro destructive processes of any etiology are related to problematic and 
socially important diseases due to ineffective therapeutic strategy and need to search for 
new successful ways of treatment and rehabilitation of patient with cerebral infarctions 
and brain attacks
Aims: Authors plant overify hypothesis on viability of additional use of perineural 
implantation of autologous mesenchymal stem cells (MSC) in order to optimize standard 
therapy of patients with brain attacks. Such combined technology is aim datextra 
activation of brain plasticity mechanisms during development of neuro destructive 
processes. 
Methods: The technique of MSC perineural migration to injured brain regions was 
experimentally verified on rats (n=40) paying attention to somatotopic organization of 
cranial nerves.
This technique was clinically tested in pilot project. Phenotyping of autologous MSC from 
adipose tissue (AT) was performed in 23 patients with brain attacks. These 23 patients 
received standard treatment as per international guidelines together with three perineural 
implantations of autologous MSC from AT with 5-9days intervals. The other group of 
patients (n=7) received only standard therapy as per international guidelines. 
Results: Additional use of cell therapy resulted in more rapid and effective recovery of 
disordered neurological functions in all cases compared to those who received standard 
therapy. The phenomenon of abrupt recovery of neurological functions was established 
during first 24hours after each injection of autologous MSC. Cumulative recovery of 
functions progressed after each implantation. 
Discussion and conclusion: Experimentally developed technique of perineural implantation 
of autologous MSC was successfully verified in clinical conditions in accordance with 
certified cell therapy guideline (The Ministry of Health of the Republic of Belarus) in 
combination with standard treatment of patients with cerebral infarctions. Cell therapy 
with autologous MSC from AT by means of perineural delivery to injured brain regions is 
the basis for activation of reparative potential of nerve tissue and progressive recovery of 
neurological functions in patients with cerebral infarctions.          
Keywords: brain attack, stem cells, perineural migration, somatotopic principle, brain 
plasticity
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with attention to somatotopic principle of exogenous SC distribution 
in the area of brain injuries.
Material and methods
Experimental stage
Wistar rats (n=40) weighing 210-250grams was subjected to brain 
tissue removal (100µl) by aspiration with micro pipettein a stereo 
taxic device under ketamine-xylazine-acepromazine anesthesia (55.6, 
6.6 and 1.1mg/kg, respectively, i/p). Two groups of rats hadbilateral 
destructions in somatosensory (n=20) and cerebellar (n=20) cortices. 
MSCsuspension (30000 cells labelled by PKH67 green fluorescent 
linker(Sigma-Aldrich, St. Louis, MO, USA), in 50µl of phosphate-
buffered saline) was injected into sub mucosa of nasal cavity or into 
Meckel’s cave-in 10min after surgery. 10 rats from each group received 
microinjection of MSC into sub mucosa of nasal cavity (Figure 1), 
another 10 received microinjection of MSC into Meckel’s cave (Figure 
1). The method details are described.11–14 Animals were sacrificed in 
0.5, 1.0, 4.0, 8.0, 24.0 and 72.0hours and in 7, 14 and 21days after 
procedures. Brain was extracted, frozen and sliced for confocal laser 
microscopy (Zeiss AxioVert 200M fluorescent microscope with Zeiss 
Axio Cam HRm CCD camera, Carl Zeiss, Germany).
Figure 1 Scheme of stem cells injection in rat using intranasal way (left and 
infraorbital channel in to area of Gasser’s ganglionin Meckel’scave (right).
Clinical stage early passages of cell cultures of autologous MSC 
from AT have been obtained from 23 patients with brain strokes 
aged 47.4 (28.3÷65.0) at the stage of cell material preparation 
for implantation. Viability of cell cultures, proliferative potential, 
expression of standard and additional phenotypic MSC markers have 
been comparatively assessed. Concentration of gill cell-derived neuro 
trophic factor (GDNF) was estimated in MSC AT cultures of patients 
with brain strokes.
It was revealed that MSCAT cultures of patients with brain 
strokes correspond to main morpho-phenotypic criteria defined by 
International Society for Cellular Therapy, express nerve growth 
factor CD271, maintain proliferative potential and are characterized 
by spontaneous production of GDNF at early stages of cell cultures 
pass aging. Preparation was followed by three subsequent perineural 
endoscopic implantations of autologous MSC from adipose tissue in 




PKH67 signal was observed in olfactory bulb in 0.5hours and in 
somatosensory zone in 24.0hours after intranasal application in rats 
with somatosensory cortex lesion with thepeak on 14th-21st days 
(Figure 2A). The signal was vague in rats with cerebellar cortex 
lesion (Figure 2B). Conversely, the signal was detected in rats with 
cerebellar cortex lesion in caudal brainstem in 4.0 and 8.0hours and in 
cerebellar cortex in 24.0hours after microinjection into Meckel’s cave 
with the peak on 21st day (Figure 2D). Microinjection into Meckel’s 
cave was followed by weak signal in the damaged area in animals 
with somatosensory cortex lesion (Figure 2C). Our data demonstrate 
targeted migration of mesenchymal stem cells towards brain tissue of 
anterior and posterior cranial fossa depending on the way of delivery 
(olfactory or trigeminal routes).
Figure 2 Fluorescent photographs showing the PKH67 labelled cells 
on 21stday after surgery in the lesioned brain areas contralateral to 
microinjection site. A and B following intranasal microinjection, C and D 
following microinjection into Meckel’s cave.
Clinical stage 
Good to lerability of cell therapy and absence of toxicreactions 
and other side effects mwere registered in all 23 cases of perineural 
injection of MSC AT. Stable and pronounced recovery of neurological 
functions was noted during first 24hours after each MSC injection, 
and it preserved in future. Initial assessment of neurologic deficiency 
according to NIHSS scale15 in 14 patients with initial cerebral 
infarctions who received both perineural MSC AT and ongoing 
standard therapy was 10.1 points and 1.9 points in 6months; no one had 
re-infarction. Initial assessment of neurologic deficiency according to 
NIHSS scale in 9patients with multiple secondary cerebral infarctions 
after old intracranial hemorrhages was 27.8 points and 14.2 points in 
6months after standard therapy combined with perineural injection of 
MSC AT.
Initial assessment of neurologic deficiency according to NIHSS 
scale in 7 patients who received only standard therapy was 11.6 points 
and 10.2 points in 6 months; two of them (28.6%) had cerebral re-
infarctions.
Conclusion
Therefore, cell therapy with autologous MSC from AT by means 
of perineural delivery to brain has pronounced positive effect on 
recovery of neurological functions in patients with brain attacks. This 
effect is based on the principle of somatotopic migration of SC along 
cranial nerve fibers to brain injuries in specific regions. Less traumatic 
delivery of exogenous autologous MSC to injured brain regions 
contribute to activation of reparative processes in nerve tissue and 
effective recovery of neurological functions in patients with cerebral 
infarctions.
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